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Summary
Background: Variants in POLG are one of the most common causes of
inherited mitochondrial disease. Phenotypic classification of POLG disease
has evolved haphazardly making it complicated and difficult to implement in
everyday clinical practise. The aim of our study was to simplify the classifica-
tion and facilitate better clinical recognition.
Methods: A multinational, retrospective study using data from 155 patients
with POLG variants recruited from seven European countries.
Results: We describe the spectrum of clinical features associated with POLG
variants in the largest known cohort of patients. While clinical features
clearly form a continuum, stratifying patients simply according to age of
onset—onset prior to age 12 years; onset between 12 and 40 years and onset
after the age of 40 years, permitted us to identify clear phenotypic and prog-
nostic differences. Prior to 12 years of age, liver involvement (87%), seizures
(84%), and feeding difficulties (84%) were the major features. For those with
onset between 12 and 40 years, ataxia (90%), peripheral neuropathy (84%),
and seizures (71%) predominated, while for those with onset over 40 years,
ptosis (95%), progressive external ophthalmoplegia (89%), and ataxia (58%)
were the major clinical features. The earlier the onset the worse the progno-
sis. Patients with epilepsy and those with compound heterozygous variants
carried significantly worse prognosis.
Conclusion: Based on our data, we propose a simplified POLG disease classi-
fication, which can be used to guide diagnostic investigations and predict dis-
ease course.
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1 | INTRODUCTION
Mitochondria are intracellular organelles found in almost
all human cells. Their key function is the production of
adenosine triphosphate through the process of oxidative
phosphorylation performed by the mitochondrial respira-
tory chain (MRC). The MRC comprises more than 90 pro-
teins organised into five complexes (I-V). Mitochondrial
DNA (mtDNA) codes for 13 proteins while the remaining
proteins are encoded by nuclear DNA.1 The enzyme that
replicates and repairs mtDNA, polymerase γ,2 is a
heterotrimer comprising a catalytic subunit (POLG) and
two accessory subunits (POLG2). Mutations in POLG
(OMIM * 174763), the nuclear gene encoding the cata-
lytic subunit, interfere with mtDNA maintenance.2,3
Variants in POLG are the single most common cause of
inherited mitochondrial disease.4 The first POLG variant
associated with disease was described in a family with auto-
somal dominant progressive external ophthalmoplegia
(PEO5), but since then, more than 190 disease-causing
variants have been identified (http://tools.niehs.nih.giv/
polg). POLG variants are associated with a wide spectrum
of overlapping phenotypes ranging from devastating fatal
neonatal disease to a mild late onset disease with myopa-
thy and PEO. A summary of the major POLG-related
phenotypes reported in the literature4,6-22 is provided in
Table 1.
The clinical features of POLG disease are extremely
heterogeneous making early clinical recognition chal-
lenging. The increasing numbers of terms that have been
used to describe the clinical phenotypes (Table 1) have
added to this confusion.
The clinical reports published so far were based
on small numbers of patients and did not describe
the clinical spectrum through the whole life span.
Longitudinal studies describing the natural history of
the disease in a large cohort of patients are still
lacking.
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In this study, we aimed to describe the natural history
of POLG disease in the largest cohort of patients with
confirmed POLG variants, focusing on the clinical fea-
tures and the biomarkers which may predict the long-
term prognosis. We aimed to provide a simpler clinical
classification to facilitate early clinical recognition of
patients with POLG disease.
2 | METHODS
2.1 | Study design, population, and
data collection
We performed a multinational, retrospective study of
patients from 12 centres in seven European countries:
TABLE 1 Summary of the major syndromes associated with POLG mutations reported in the literature
Phenotype nomenclatures
(reference) Major clinical features Age of onset
1 Myocerebrohepatopathy (MCHS)9,18,22 Myopathy, hypotonia, developmental delay,
encephalopathy, liver failure.
Neonate, early infancy
2 Alpers-Huttenlocher Syndrome
(AHS)9,11,17
Encephalopathy, psychomotor regression, refractory
epilepsy liver dysfunction
Infancy, childhood,
adolescence
3 Alpers syndrome4,13,14 Synonym of AHS As in AHS
4 Alpers-Huttenlocher like21 Synonym of AHS As in AHS
5 Infantile hepatocerebral syndrome9 Includes AHS and MCHS Neonate, infancy,
childhood
6 Infantile mitochondrial DNA depletion
syndrome19
Includes both AHS and MCHS Infancy, childhood
7 Leigh like19 Psychomotor retardation, hypotonia, extrapyramidal
dysfunction, symmetrical hyperintensities on T2
weighted images in basal ganglia, brain stem,
thalamus
Infancy
8 Mitochondrial Neuro-Gastro-Intestinal
Encephalopathy (MNGIE) like13,14,20
Severe gastrointestinal dysmotility, encephalopathy,
ptosis ophthalmoplegia, peripheral neuropathy
Childhood, adolescence
adulthood
9 Myoclonus, epilepsy, myopathy, and
sensory ataxia (MEMSA)4
Epilepsy, myopathy, ataxia, liver dysfunction,
headache and stroke-like episodes
Adolescence, adulthood
10 Spinocerebellar ataxia with epilepsy
(SCAE)4,7
Now incorporated under MEMSA umbrella As in MEMSA
11 Mitochondrial spinocerebellar ataxia
with epilepsy (MSCAE)6
Now incorporated under MEMSA umbrella As in MEMSA
12 Ataxia neuropathy spectrum (ANS)4,7 Ataxia, neuropathy, psychiatric symptoms, cognitive
impairment, epilepsy, and ophthalmoplegia
Adolescent and adult
13 Mitochondrial recessive ataxia
syndrome (MIRAS)10
Now incorporated under ANS umbrella As in ANS
14 Sensory ataxia neuropathy dysarthria
and ophthalmoplegia (SANDO)4
Now incorporated under ANS umbrella As in ANS
15 Mitochondrial encephalomyopathy,
lactic acidosis, and stroke-like
episodes (MELAS) like phenotype23
Headache, seizures, stroke-like episodes as in
MEMSA
Adult
16
Recessive Charcot-Marie tooth like12 Axonal polyneuropathy, muscle weakness, wasting,
tremor nystagmus, dysarthria, dysmetria, and
dysdiadochokinesis.
Adult
17 Parkinsonism8,16 Tremor, rigidity, hypo/bradykinesia, balance
disturbance
Adult
18 Autosomal recessive progressive
external ophthalmoplegia (arPEO)5,7
Ptosis, ophthalmoparesis, may be associated with
ataxia and myopathy
Adult, elderly
19 Autosomal dominant progressive
external ophthalmoplegia (adPEO)5,7
Ptosis, ophthalmoparesis, myopathy, neuropathy,
ataxia
Adult-elderly
20 Chronic progressive external
ophthalmoplegia plus(CPEO+)7
Synonym of adPEO Adult-elderly
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Norway (Haukeland University Hospital, Oslo University
Hospital, St. Olav's Hospital and University Hospital of
Northern Norway); United Kingdom (Great Ormond
Street Hospital, London); Sweden (Centre for Inherited
Metabolic Diseases, Karolinska University Hospital,
Stockholm and The Queen Silvia Children's Hospital,
University of Gothenburg); Denmark (Department of
Clinical Genetics, Copenhagen University Hospital); Fin-
land (Children's Hospital, Helsinki University Hospital
and Clinic for Children and Adolescents, Oulu University
Hospital); Netherlands (Department of Genetics and Cell
Biology, Maastricht University, Maastricht); and Spain
(Sant Joan de Déu Children's Hospital, Barcelona).
Patients diagnosed and followed at the participating cen-
tres were considered eligible if they had recessive disease
and confirmed biallelic pathogenic/likely pathogenic
POLG variants or dominant disease and heterozygous
confirmed pathogenic variants. Data entry was completed
in December 2017.
Detailed clinical, biochemical, muscle biopsy, neuro-
physiological, neuroimaging, and genetic data were
obtained by using an electronic-case report form com-
pleted by the responsible investigator(s) at each centre
and reviewed by the study-principal investigator (O.H.).
The date of disease onset was defined by the date of
the first symptom(s) requiring medical evaluation. End of
follow up was defined as the date of the patient's last visit
to the follow-up centre or death. Available longitudinal
data, both at disease onset and later during the disease
course, were collected. Liver involvement was defined by
the presence of two or more of the following parameters
in at least two different time points; elevated aspartate
aminotransferase, gamma-glutamyltransferase, bilirubin
or ammonia, low serum albumin, or pathological histo-
logical findings of liver biopsy. The presence of anaemia
and abnormal cerebrospinal fluid (CSF) protein and/or
albumin was identified as described in previous publica-
tions.13,14,24 We use the recent International League
Against Epilepsy (ILAE) classification25 for seizure
classification.
2.2 | Data and statistical analysis
Detailed descriptive data analysis was performed on the
entire study cohort using SPSS (Statistical Package of
Social Sciences), Version 23.0. A two sided P value less
than .05 was considered to be statistically significant.
Mosaic plots was performed by using R (The R founda-
tion for statistical computing), version 3.6.1.
In order to simplify the clinical classification patients
were grouped according to the age of disease onset into
three groups: (a) those with disease onset prior to the age
of 12 years (before puberty), (b) those with disease onset
between 12 and 40 years, and (c) those with disease onset
after the age of 40 years. The age of onset of each individ-
ual symptom was recorded and classified according to
these three defined age-groups. Correspondence analysis
was performed to examine the relationship between two
variables (groups of patients who were classified
according to the age of onset as described and the age of
onset of each individual symptom) graphically in a multi-
dimensional space; this allowed examination of the clus-
tering of symptoms around each age group. Further,
mosaic plots was performed to study the differences
between the above mentioned groups. The study cohort
was also classified according to the presence or absence
of epilepsy, regardless the age of onset.
For survival analysis, the end-point was time to death
which was defined as the time in months from the date
of disease onset to the date of death. Univariate survival
analysis was performed using log-rank test (Kaplan-
Meier) to compare differences in survival time between
categories.
3 | RESULTS
3.1 | Demography
One hundred and fifty-five patients, (males n = 76 [49%],
females n = 79 [51%]) with confirmed pathogenic POLG
variants were identified. Seventy-six were diagnosed in
Norway, 44 in Sweden, 19 in the United Kingdom,
8 in Finland, 5 in Denmark, 2 in The Netherlands, and
1 in Spain. The majority of patients were Northern
European (n = 146), while three patients were from Iraq,
two from Cyprus and one from Croatia, Pakistan, Spain,
and the United Arab Emirates.
3.2 | Major clinical features
Median age at disease onset for the whole study cohort
was 10 years (range: birth—71 years). Disease onset prior
to the age of 12 years occurred in 54% (n = 83/155),
between 12 and 40 years of age in 34% (n = 53/155), and
after the age of 40 years in 12% (n = 19/155) had. Disease
debut was apparently spontaneous in 113/155 (73%),
followed an infectious illness in 32/155 (21%) and not
clearly reported in 10/155 (6%) of the patients.
Neurological (90%, n = 139/155), ophthalmological
(74%, n = 112/151), and gastrointestinal symptoms (63%,
n = 92/146) were the most predominant clinical features.
Epilepsy was reported in 69% (n = 107/155), with focal
and focal evolving to bilateral tonic-clonic seizures being
HIKMAT ET AL. 729
TABLE 2 Major clinical features of patients reported in this study
Major clinical features
Number of
patients
Number of
patients at onset
Number of
patients later
1. Neurological
Seizure 107/154 (69%) 73/106 (69%) 33/106 (31%)
Focal 94/102 (92%) 60/91 (66%) 31/91 (34%)
Focal evolving to bilateral tonic-clonic 85/100 (85%) 43/85 (51%) 42/85 (49%)
Myoclonic 73/98 (74%) 26/71 (37%) 45/71 (63%)
Epilepsia partialis continua 52/91 (57%) 15/52 (29%) 37/52 (71%)
Convulsive status epilepticus 79/101 (78%) 30/78 (38%) 48/78 (62%)
Othersa 11/80 (14%) 5/10 (50%) 5/10 (50%)
Ataxia 87/138 (63%) 53/85 (62%) 32/85 (38%)
Hypotonia 68/135 (50%) 50/66 (76%) 16/66 (24%)
Limb weakness 89/125 (71%) 33/83 (40%) 50/83 (60%)
Migraine-like headache 52/143 (36%) 38/52 (73%) 14/52 (27%)
Peripheral neuropathy 65/123 (53%) 23/63 (36%) 40/63 (64%)
Sensorineural hearing loss 16/146 (11%) 9/16 (56%) 7/16 (44%)
2. Ophthalmological
Ptosis 51/149 (34%) 28/49 (57%) 21/49 (43%)
Progressive external ophthalmoplegia 56/146 (38%) 24/56 (43%) 32/56 (57%)
Nystagmus 55/146 (38%) 29/53 (55%) 24/53 (45%)
Cataract 11/148 (7%) 2/9 (22%) 7/9 (78%)
Cortical blindness 32/111 (29%) 17/29 (59%) 12/29 (41%)
Pigmentary retinopathy 3/140 (2%) 1/2 (50%) 1/2 (50%)
3. Gastrointestinal
Feeding difficulties 75/145 (52%) 36/73 (49%) 37/73 (51%)
Vomiting 52/137 (38%) 31/49 (63%) 18/49 (37%)
Chronic diarrhoea 8/136 (6%) 2/8 (25%) 6/8 (75%)
Liver involvement 95/151 (64%) 35/93 (38%) 58/93 (62%)
Othersb 7/128 (5%) 2/7 (29%) 5/7 (71%)
4. Endocrinological
Diabetes mellitus type 1 1/151 (1%) 0/1 (0%) 1/1 (100%)
Diabetes mellitus type 2 2/151 (1%) 2/2 (100%) 0/2 (0%)
Adrenal insufficiency 2/151 (1%) 1/2 (50%) 1/2 (50%)
Growth hormone deficiency 2/147 (1%) 1/2 (50%) 1/2 (50%)
Othersc 3/140 (2%) 0/3 (0%) 3/3 (100%)
5. Others
Anaemia 77/136 (57%) 20/77 (26%) 57/77 (74%)
Renal disordersd 13/149 (8%) 3/12 (25%) 9/12 (75%)
Respiratory disorderse 18/149 (12%) 5/18 (28%) 13/18 (72%)
aOne infantile spasms, eight absence, one atonic seizure, and one non convulsive status epilepticus.
bOne Coeliac disease, one constipation, one paralytic ileus, one acute colon necrosis, one gastrointestinal bleeding, one colitis, and one milk protein
intolerance.
cOne hypothyroidism, one hypoparathyroidism, and one pseudo hypoparathyroidism.
dSeven renal tubular acidosis, five renal failure, and one renal stone.
eTwo asthma, one chest deformity, two recurrent chest infections, two sleep apnoea, elven hypoventilation/respiratory insufficiency.
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the most common seizure types (92%, n = 94/102). Ataxia
(63%, n = 87/138), peripheral neuropathy (53%,
n = 65/123), and hypotonia (50%, n = 68/135) were fre-
quently reported. Nystagmus (38%, n = 55/146), PEO
(38%, n = 56/146), and ptosis (34%, n = 51/149) were the
most commonly reported ophthalmological features.
Liver involvement was identified in 64% (n = 96/151) of
the patients. More than half of the study cohort had feed-
ing difficulties (52%, n = 75/145), regardless of the age of
onset. A detailed description of the clinical features is
provided in Table 2.
3.3 | Age-related clinical features
We found clear evidence that the clinical features of
POLG disease form a continuum (Figure 1) rather than
distinct phenotypes (Table 1). Nevertheless, by grouping
the patients into three groups according to the age of
onset (early, juvenile/adult, and late onset groups), we
could identify clear phenotypic and prognostic differ-
ences (Table 3). To confirm this finding, correspondence
analysis was performed and demonstrated clear cluster-
ing of the symptoms around the three different age
groups as illustrated in Figure S1. Further, mosaic plots
showed there was a statistically significance differences
in the phenotypes between the above mentioned groups
(Figure S2).
3.4 | Laboratory, muscle biopsy, and
neurophysiological findings
The percentage of those with raised lactate in serum and
CSF at disease onset was 35% (n = 29/84) and 40%
(n = 19/47), respectively. Abnormal elevated CSF protein
at disease onset was reported in 68% (n = 44/68) of
patients. In muscle biopsies, the presence of ragged-red
fibres, COX-negative fibres, and abnormal respiratory
chain activities was reported in fewer than the half of
those who had been investigated (Table S1).
Electroencephalogram recordings showed that
approximately half (54%, n = 58/107) of patients with
epilepsy had epileptiform activities over the occipital
lobes. Abnormal nerve conduction was observed in 70%
0 24 48 72
Anaemia
PEO
Ptosis
Muscle weakness
Peripheral neuropathy
Ataxia
Liver dysfunction
Stroke like episodes
Seizure
Age at onset in years
FIGURE 1 Age of onset of each
individual symptom in patients with
POLG disease. Range I, Median. PEO,
progressive external ophthalmoplegia
TABLE 3 The onset of symptoms according to three age
groups
Symptoms
<12 years 12–40 years >40 years
83/155 (54%) 53/155 (34%) 19/155 (12%)
Seizures 69/82 (84%) 37/52 (71%) 1/19 (5%)
Ataxia 30/67 (45%) 46/51 (90%) 11/19 (58%)
Hypotonia 57/72 (79%) 9/44 (20%) 2/18 (11%)
Stroke-like
episodes
26/73 (36%) 26/48 (54%) None (0%)
Peripheral
neuropathy
17/57 (30%) 38/45 (84%) 10/18 (65%)
Migraine-like
headache
14/52 (27%) 36/52 (69%) 2/52 (4%)
Feeding
difficulties
58/69 (84%) 13/47 (28%) 4/18 (22%)
Liver
involvement
71/82 (87%) 23/49 (47%) 2/19 (11%)
Anaemia 49/71 (69%) 25/45 (56%) 3/16 (19%)
Ptosis 12/78 (15%) 21/50 (42%) 18/19 (95%)
PEO 7/83 (8%) 32/48 (67%) 17/19 (89%)
Survival time
in months
19 (0.5–600) 151 (4–487) 191 (17–336)
Median (Range)
Abbreviation: PEO, progressive external ophthalmoplegia.
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(n = 43/61) of the individuals, the majority of those (81%,
n = 35/43) had axonal neuropathy. None had a pure
demyelinating neuropathy (Table S1).
3.5 | Neuroimaging findings
General cerebral atrophy (59%, n = 35/59) and cortical
focal lesions (54%, n = 59/108) manifesting as T2/FLAIR
hyperintensities affecting cortical and subcortical areas
were the most frequently reported magnetic resonance
imaging (MRI) abnormalities in the study group as a
whole. These imaging findings were more prevalent in
patients with epilepsy compared to those without epi-
lepsy. A detailed description of MRI findings is provided
in Table S2.
3.6 | Genetic findings
POLG variant(s) for each case were identified either by
targeted variant analysis for specific common variants
(c.1399G>C, p.Ala467Thr and c.2243G>C, p.Trp748Ser)
or by sequence analysis of all coding regions of the POLG
gene. All POLG variants identified in this study are illus-
trated in igure S3 and the individual mutation results are
available on request.
A total of 41 different POLG variants were identified in
the 155 individuals described in this study. Ninety patients
had compound heterozygous variants, 59 had homozygous
variants, and 6 patients had a heterozygous variant
associated with autosomal dominant disease, mainly auto-
somal dominant progressive external ophthalmoplegia. The
majority (n = 58/83) of patients with early onset disease
(before the age of 12 years) had compound heterozygous
pathogenic POLG variants (regardless of the variant types).
The opposite was found in those with juvenile/adult
onset disease in whom the majority (n = 32/52) had
homozygous pathogenic variants. Frequency data for the
homozygous variant c.1399G>C, p.(Ala467Thr, com-
pound heterozygous variants c.1399G>C, p.(Ala467Thr)/
c.2243G>C, p.(Trp748Ser), and the homozygous variant
c.2243G>C, p.(Trp748Ser) for each of the three age
groups are provided in Table S3.
3.7 | Survival analysis
Of the155 patients, 61 were alive at the time of data anal-
ysis and one had been lost to follow-up. Median age at
death was 7.4 years (range 1 month to 91 years). The
main cause of death was liver failure (32%, n = 30/93),
followed by infection/sepsis (20%, n = 19/93), multi-
organ failure (19%, n = 18/93), status epilepticus (14%,
n = 13/93), one suicidal death. The cause of death was
unknown in 13% (n = 12/93) of the individuals.
Further analysis showed that median survival time
from disease onset to death was 19 months (range
0.5-600 months, interquartile range [IQR] 111) for those
with disease onset prior to the age 12 years, 151 months
(range 4-487, IQR 255) for those with disease onset
between 12 and 40 years, and 191 months (range 17-336,
FIGURE 2 Survival analysis. A, Kaplan-Meier curve comparing survival of those with seizures and those without seizures and showed
those with seizures carried significantly worse survival. B, Kaplan-Meier curve comparing survival of those with homozygous variants and
those with compound heterozygous POLG variants and showed those with compound heterozygous variants carried significantly worse
survival
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IQR 101) for those with disease onset after the age of
40 years.
The presence of epilepsy was associated with signifi-
cantly worse survival (P < .001), and the median survival
time from seizure onset to death was 37 months (range
<1-487). Survival analysis also showed that patients with
pathogenic compound heterozygous POLG variants had
significantly (P < .001) worse survival compared to those
with pathogenic homozygous variants, regardless of spe-
cific variant types (Figure 2). Further analysis showed
that survival after the onset of seizures in those with early
onset disease was significantly worse than those who
developed seizures as part of juvenile/adult onset disease.
Further, patients who developed liver involvement
showed a significantly worse survival than those without
liver impairment (Figure S4).
4 | DISCUSSION
We present the detailed description of 155 patients with
confirmed pathogenic POLG variants focusing on the
clinical features, but including laboratory, genetic, and
neuroimaging findings. As far as we can ascertain, this is
the largest cohort of patients with POLG disease so far
described. In addition to the descriptive element, we have
also analysed factors, which may predict the prognosis.
We defined the age of onset of each individual symp-
tom and our data confirms that POLG disease comprises
a continuum of clinical features rather than a set of sepa-
rate clinical identities (Figure 1). Apart from PEO/ptosis,
all other symptoms could start from infancy to adult-
hood. While hypotonia and feeding difficulties in infants
are likely due to different pathological processes than
these features appearing in adults, seizures, peripheral
neuropathy, ataxia, muscle weakness, and hepatic distur-
bance have a similar basis and all could present at any
age. PEO/ptosis starts later and appears mainly in
patients with dominantly inherited disease or in those
with juvenile/early adult onset disease who do not
develop epilepsy or, less often, survive despite it. Stroke-
like episodes appear to start slightly later than most other
features. This may reflect the nature of the process26,27
namely that these represent prolonged seizure activity or
status epilepticus.
If we look at the median ages of onset, instead of
looking at the age range, we do see a tendency for the
features to cluster according to age. We, therefore,
reanalysed the data using different age groups. Based on
these findings, we found that the clinical spectrum of
POLG disease was best described by grouping patients
into three categories of early, juvenile/adult, and late
onset. Early onset disease was classified as beginning
prior to the age of 12 years. In these patients, liver
involvement, feeding difficulties, seizures, hypotonia, and
muscle weakness were the most dominant/important
clinical features and this group had the worst prognosis.
The juvenile/adult onset form (12-40 years of age) was
characterised by peripheral neuropathy, ataxia, seizures,
stroke-like episodes and, in patients with longer survival,
PEO. This group carried a better prognosis than the early
onset group. Late onset disease (after the age of 40 years)
was characterised by ptosis and PEO, with additional fea-
tures such as peripheral neuropathy ataxia and muscle
weakness occurring frequently. This group had the best
prognosis. Thus, while the clinical features associated
with POLG variants can present at any age, age of disease
onset provides both clues to the diagnosis and informa-
tion about the outcome (Table 3).
The most frequently reported neurological features,
included seizures, ataxia, and peripheral neuropathy.
Focal evolving to bilateral tonic-clonic seizures were the
most common seizure types, with epileptiform activities
predominantly seen in occipital regions. These findings
are consistent with previous reports (8,10,13-15,28,29), how-
ever, our results also showed that seizures were the most
predominant clinical feature in patients with early onset
disease (<12 years), common in those with juvenile/adult
onset (12-40 years), but infrequent in those with late
onset disease (>40 years). Ataxia, peripheral neuropathy,
and migraine-like headache were most predominant in
individuals with juvenile/adult onset disease, although
reported in both early and late onset disease. Ptosis and
PEO were common in late onset disease as reported
previously,22 however our data showed that the onset of
ptosis and PEO occurred in all age groups. The onset of
gastrointestinal features such as feeding difficulties and
liver involvement occurred at any age, but was predomi-
nantly seen in patients with early onset disease.
Demographic data showed that more than half of the
individuals included in this study had onset during child-
hood (prior to the age of 12), and the incidence of the dis-
ease decreased with age. Contrary to previous
publications,9,15 which demonstrate some male predomi-
nance, we observed no gender difference.
Survival analysis demonstrated a clear correlation
between the age of disease onset and the survival time;
earlier onset was associated with worse prognosis
(Table 3). Further analysis showed that the presence of
epilepsy was significantly associated with worse progno-
sis regardless of the age of disease onset, and individuals
harbouring compound heterozygous POLG variants had
worse prognosis compared to those with homozygous
variants.
Our study showed that laboratory investigations which
are commonly used in the initial diagnostic work-up of
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mitochondrial disorders, for example, raised blood and
CSF lactate, the presence of ragged-red/COX-negative
fibres and abnormal respiratory chain activities in the skel-
etal muscle have low diagnostic sensitivity, being present
in fewer than 50% of the individuals. As we showed in a
previous publication,24 elevated CSF protein was the most
sensitive (68%, n = 44/65) laboratory diagnostic biomarker
at disease onset.
The majority of the patients included in this study were
of Northern European descent; thus, a possible limitation
of this study is that it might not be possible to extrapolate
our findings to other ethnic groups. However, we provide
detailed description of all the known phenotypes associ-
ated with POLG disease related to more than 40 different
POLG variants. Moreover, there is little evidence in the lit-
erature of marked ethnic differences in phenotypic
expression of POLG disease. Based on the diverse geno-
typic background of our population, we consider that the
findings of our study are relevant to patients with POLG
disease, regardless of the ethnic background.
A simple and robust clinical classification is the cor-
nerstone of early diagnosis. Such a classification, together
with diagnostic investigations, should facilitate easy rec-
ognition of the disease and be useful for both experts and
physicians with limited experience of the field. Current
nomenclature describing the phenotypic spectrum of
POLG disease (Table 1) is complicated and includes over-
lapping clinical syndromes. This makes implementation
in everyday clinical practice difficult. A clear and accu-
rate classification that describes the full spectrum of dis-
ease taking account of age-related features is essential
not only for optimal management, but also for research
FIGURE 3 Diagnosing POLG disease; clinical suspicion and relevant investigations according to the age of onset. While we have
shown that POLG clinical features form a continuum, but it is also clear that age plays a role in which features predominate. Based on our
age groups, we can see clear clinical patterns and these will dictate which investigations are appropriate and useful. For example, in the
older age category, PEO and ataxia dominate the clinical spectrum and in these cases one can choose either to screen the known genes or to
take a muscle biopsy which give both structural clues (COX negative fibres) and the possibility to examine mtDNA (for multiple deletions).
We also see that the typical occipital epilepsy occurs in the younger two categories and it is in these that MRI imaging also provides
important clues. Peripheral neuropathy occurs in all age groups. In earlier studies, we showed that elevated CSF protein can be helpful, for
example in a child with epilepsy and focal MRI changes it can be an important indicator of poor prognosis. a: Direct POLG gene sequence
analysis is recommended to confirm the diagnosis in a case of strong clinical suspicion. b: Absence of these findings does not exclude the
diagnosis of POLG disease. c: targeted variant analysis for the most common variants (p. Ala467Thr and p.Trp748Ser) can be performed first
in juvenile and late onset disease, whole POLG gene sequence analysis is recommended for all early onset disease and those with strong
clinical suspicion of POLG disease regardless of the age of onset. CSF, cerebrospinal fluid; RRF, ragged-red fibres; PEO, progressive external
ophthalmoplegia; P. neuropathy, peripheral neuropathy; SLE, stroke- like episodes
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and, when treatments become available, for use in clini-
cal trials.
We provide a robust and simplified clinical classifica-
tion based on data from the largest cohort of patients
with POLG disease published to date. This classification
highlights three distinct age groups and within these
groups the major clinical features. Earlier classifications
of POLG disease have focused primarily on phenotypic
elements; for example, the presence of ataxia with or
without myoclonus or epilepsy has variously been
referred to as SANDO, ANS, or MIRAS/MSCAE. Early
onset diseases have been separated into Alpers or MCHS
or Leigh-like syndromes. The presence of mtDNA deple-
tion has also been used to define POLG related disease
although the presence of this is known to be tissue
dependent and depletion in brain and liver is found in
both young and older patients. We feel that these pheno-
typic labels create an unnecessarily complicated classifi-
cation. Age alone appears robust enough to delineate the
important features of POLG disease such that we would
recommend simplifying classification to early onset, juve-
nile onset and late onset POLG disease. The algorithm
(Figure 3) shows how recognition of these key clinical
features could be used to direct clinical investigation in
the different age groups.
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